Abstracts tagged "osteoarthritis and therapeutic targeting"

Abstract Number: 1048 • 2018 ACR/ARHP Annual Meeting
Identification of Novel Molecules with Senolytic and Autophagy Activity As Osteoarthritis Therapeutics
Uxia Nogueira-Recalde¹, Francisco J Blanco¹, Maria I. Loza², Diego Grassi³, Paul Robbins³, Eduardo Dominguez⁴ and Beatriz Carames¹, ¹Cartilage Biology Group, Rheumatology Division, INIBIC-CHUAC, A Coruña, A Coruña, Spain, ²BioFarma Research Group. University of Santiago de Compostela, santiago de Compostela, Spain, ³Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL, ⁴BioFarma Research Group. University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose: Disease-modifying treatments for Osteoarthritis (OA) are not available. Aging-related features such as failure of homeostasis mechanisms, including autophagy, cause extracellular matrix damage, chondrocyte senescence…
Abstract Number: 905 • 2017 ACR/ARHP Annual Meeting
Regenerating Cartilage and Reversing Osteoarthritis (OA) Stimulation of Adenosine A2A Receptors (A2AR) Increases Cartilage Volume and Matrix in Vitro and In Vivo
Carmen Corciulo¹, Cristina Castro², Thomas Coughlin³, Tuere Wilder¹, Oran Kennedy⁴ and Bruce Cronstein⁵, ¹Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Medicine, NYU School of Medicine, New York, NY, ³Orthopaedic Surgery, NYU School of Medicine, New York, NY, ⁴Department of Anatomy, Royal College of Surgeons, Dublin, Ireland, ⁵Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: We have recently reported that endogenously produced adenosine, interacting with A2AR, is a critical autocrine factor for maintenance of chondrocyte and cartilage homeostasis and…
Abstract Number: 1931 • 2017 ACR/ARHP Annual Meeting
Targeting Cartilage Aging As Osteoarthritis Therapeutics By Drug Repurposing
Beatriz Carames¹, Uxia Nogueira-Recalde², Maria I. Loza³, Francisco J Blanco² and Eduardo Dominguez⁴, ¹Cartilage Biology Group. Rheumatology Division, INIBIC–CHUAC, A Coruña, A Coruña, Spain, ²Cartilage Biology Group. Rheumatology Division, INIBIC-CHUAC, A Coruña, A Coruña, Spain, ³BioFarma Research Group. University of Santiago de Compostela, santiago de Compostela, Spain, ⁴BioFarma Research Group. University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose: Background: Effective treatments for Osteoarthritis (OA) are not available. In aging-related diseases, including OA, failure of cellular homeostasis mechanisms, such as autophagy can cause…
Abstract Number: 2129 • 2016 ACR/ARHP Annual Meeting
Extracellular Adenosine Deficiency Plays a Role in the Pathogenesis of Osteoarthritis (OA) and Adenosine Replacement Prevents Post-Traumatic Osteoarthritis
Carmen Corciulo¹, Matin Lendhey², Tuere Wilder¹, Oran Kennedy² and Bruce Cronstein³, ¹Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Orthopaedic Surgery, NYU-School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Extracellular adenosine is highly regulated and plays an important homeostatic role via occupancy of cell surface receptors (A1R, A2AR, A2BR, A3R). Mice lacking A2AR…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].